查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球肠道管理系统市场 -2023-2030
市场调查报告书
商品编码
1374807

全球肠道管理系统市场 -2023-2030

Global Bowel Management Systems Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

肠道管理系统 (BMS) 是一种临时遏制装置，适用于卧床或行动不便的失禁患者，肠道控制很少或没有，粪便呈液体或半液体。它们也适用于严重烧伤患者，以管理其肠道功能，促进生殖器、会阴或肛门皮肤移植的癒合，并在整形手术后保持感染控制。

只有在考虑了所有其他大便失禁管理替代方案后，才应插入用于控制大便失禁的肠道管理系统。使用肠道管理系统必须在对患者进行全面评估后与负责患者护理的医疗团队达成一致。

考虑到的病人：感染控制、设备相关皮肤破损的风险、隐私和尊严以及使用禁忌。

除了防止感染传播之外，肠道管理系统还可以防止粪便细菌污染位于腹股沟区域的尿管、静脉导管和动脉导管，导致局部和全身感染。

市场动态：驱动因素与限制因素

技术进步和产品推出的兴起

肠道管理系统的进步和主要参与者推出的新产品的增加将进一步推动预测期内的市场成长。

例如，2023 年 4 月，NHS 基金会信託旗下的数位健康公司 health call 推出了一个针对膀胱和肠道问题的自我推荐平台，让用户自行参考该信託网站的服务，而无需去看全科医生。该平台简化了寻求帮助和支持的过程，让用户提供准确、真实的推荐，这些推荐更容易被信託机构分类。

该平台于 2023 年推出，显着改善了分诊并加快了转诊速度，使患者能够全天候 (24/7) 获得服务。该解决方案还为转介提供清晰的审计追踪并加快流程。科技在膀胱和肠道护理方面发挥着越来越大的作用，九家 NHS 信託公司紧随其后，英国新创公司 Motilent 则获得了国家健康与护理研究所的资助。

此外，2022年2月，全球领先的造口护理产品製造商之一康乐保今年在新加坡推出了最新的创新产品SenSura Mio。新加坡是东南亚第一个推出 SenSura Mio 的国家，旨在改善造口者或经历过造口但现在仍患有造口的人的生活品质。

此外，发炎性肠道病患疾病率的上升、老年人口的增加、各种肠道管理产品的推出、最近和新的潜在批准以及有利的报销政策，将进一步推动预测期内的市场成长。

市场动态：克制

患者偏好大便失禁的非侵入性临床治疗。目前，大便失禁可以透过侵入性（手术）或非侵入性方式进行治疗。手术治疗的标准模式包括将生物材料注入肛管、肛管射频治疗、肛门肌肉损伤的手术修復、骶神经刺激、人工肠括约肌、肌肉转位以强化肛门括约肌以及造口。这些往往需要患者长期康復，而且非常不方便，甚至非常痛苦。

此外，缺乏认识、监管担忧和担忧的副作用也是预测期内阻碍市场成长率的因素。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按产品类型分類的片段
  • 按患者类型分類的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 科技进步的崛起
      • 主要参与者推出的产品数量增加
    • 限制
      • 患者长期康復
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按产品类型

  • 结肠造口袋
  • 灌溉系统
  • 神经调节装置
  • 其他的

第 8 章：依病患类型

  • 成年人
  • 儿科

第 9 章：按应用

  • 脊髓损伤
  • 神经系统疾病
  • 多发性硬化症
  • 中风

第 10 章：最终用户

  • 医院
  • 门诊手术中心 (ASC)
  • 其他的

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Becton, Dickinson and Company
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Coloplast Pty Ltd.
  • ConvaTec Group plc.
  • B Braun SE.
  • Consure Medical Pvt. Ltd.
  • GBUK Group Ltd.
  • Wellandmedical
  • Wellspect
  • ProSys International Ltd
  • Qufora

第 14 章：附录

简介目录
Product Code: MD7246

Overview

Bowel management systems (BMS) are temporary containment devices, indicated for bedridden or immobilised incontinent patients, with little or no bowel control, who have a liquid or semi-liquid stool. They are also indicated for patients with severe burns to manage their bowel function, promote healing of genital, perineal or anal skin grafts and maintain infection control following plastic surgery.

A bowel management system for the control of faecal incontinence should only be inserted once all other faecal incontinence management alternatives have been considered. The use of a bowel management system must be agreed upon with the medical team in charge of the patient's care following a holistic assessment of

the patient which has taken into consideration: infection control, risk of device-related skin breakdown, privacy and dignity, and contraindications for use.

In addition to preventing the spread of infection, a bowel management system can potentially prevent faecal bacterial contamination of urinary, intravenous and arterial catheters located in the groin area, causing local and systemic infection.

Market Dynamics: Drivers and Restraints

Rise in the technological advancements and product launches

The rise in the advancements in bowel management systems and novel product launches by key players will further drive the market growth during the forecast period.

For instance, in April 2023, NHS foundation trust owned digital health company health call launched a self-referral platform for bladder and bowel issues, allowing users to self-refer to services from the trust website without seeing their GP. The platform simplifies the process of seeking help and support, allowing users to give precise, factual referrals that are easier to triage by the trust.

The platform launched in 2023, has significantly improved triage and sped up referrals, allowing patients to access the service 24/7. Th,e solution also provides a clear audit trail for referrals and speeds up the process. Technology is playing a growing role in bladder and bowel care, with AI devices being trailed by nine NHS trusts and UK start-up Motilent receiving funding from the National Institute for Health and Care Research.

Moreover, in February 2022, Coloplast, one of the world's leading manufacturers of stoma care products launched its latest product innovation, the SenSura Mio in Singapore this year. Singapore is the first country in Southeast Asia that launch SenSura Mio which aims to improve the quality of life of ostomates, or people who have gone through ostomy and are now living with stoma.

Furthermore, the rise in the prevalence of inflammatory bowel diseases, the increasing geriatric population, the launch of various bowel management products, recent and new potential approvals, and Favorable reimbursement policies, will further drive the market growth during the forecast period.

Market Dynamics: Restraint

Patient preference for non-invasive clinical management of Fecal incontinence. Currently, Fecal incontinence can be managed invasively (surgically) or non-invasively. Standard modes of surgical treatment include the injection of biomaterials into the anal canal, radiofrequency treatment of the anal canal, surgical repair of anal muscle injuries, sacral nerve stimulation, artificial bowel sphincter, muscle transposition to reinforce the anal sphincter and the creation of a stoma. These often require long-term patient rehabilitation and also it is highly inconvenient and even severely painful.

Also, lack of awareness, regulatory concerns, and concerned side effects are also the factors that hamper the market growth rate during the forecast period.

Segment Analysis

The global bowel management systems is segmented based on product type, application, patient type, end-user and region.

The colostomy bags from the product type segment accounted for approximately 41.2% of the market share

The colostomy bags from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A colostomy bag is a plastic bag that collects faecal matter, also called stool or poop, from the digestive tract through an opening in the abdominal wall called a stoma. Doctors attach a bag to the stoma following a colostomy operation.

A colostomy bag, also called a stoma bag or ostomy bag, is a small, waterproof pouch used to collect waste from the body. During a surgical procedure known as a colostomy, an opening called a stoma or ostomy is formed between the large intestine (colon) and the abdominal wall. This allows waste products to be excreted through the opening in the abdominal wall rather than via the colon through the rectum and anus.

For instance, in December 2021, Coloplast launched a clinical trial to test the effect of its ostomy product, Heylo, a product that uses sensors to warn patients with colostomy bags about leakage and advise them about how to prevent it. Thus, the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors such as the rising prevalence of colorectal cancer and the growing geriatric population. Additionally, increased patient awareness, rising adoption rates of intestinal management systems, increasing investments in product development, excellently established healthcare infrastructure, and strong acceptance of developed products are some of the key factors ensuring the region's dominance.

For instance, in May 2023 Advanced Medical Balloons GmbH (formerly Creative Balloons GmbH), a specialist in medical technology from Waghaeusel near Heidelberg, stated that the company is expanding its intensive care business to the United States.

This is based on the approval which has recently been granted by the U.S. Food and Drug Administration (FDA) for their innovative catheter system hygh-tec. The novel faecal management system hygh-tec provides maximum seal and prevention of faecal leakage in patients receiving intensive care.

Moreover, in July 2021 Trio Healthcare secured a second round of funding from US specialist finance company, SWK Holdings Corporation. The funding, approximately $10m in total, will support Trio's R&D and manufacturing as it scales up operations to support a large-scale global roll-out of Trio's world-first stoma bag, GeniiTM

COVID-19 Impact Analysis

COVID-19 had a substantial impact on bowel management systems. Amidst the outbreak of the COVID-19 pandemic, there has been a rise in other health complications that rose with COVID-19 infections. According to a report by the surveillance epidemiology of coronavirus Under Research Exclusion (SECURE-IBD) database published in January 2022 mentioned that adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with inflammatory bowel disease (IBD).

Competitive Landscape

The major global players in the bowel management systems market include: Becton, Dickinson and Company, Coloplast Pty Ltd., ConvaTec Group plc., B Braun SE., Consure Medical Pvt. Ltd., GBUK Group Ltd., Wellandmedical, Wellspect, ProSys International Ltd Qufora and among others.

Key Developments

  • In April 2022, Microbiotica received project funding from the crohn's and colitis foundation as a part of their inflammatory bowel disease ventures program for the development of therapies to treat inflammatory bowel disease.
  • In November 2021, Medtronic plc, a global leader in healthcare technology, stated that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, a combination intended to ensure both timely and accurate results for patients from the comfort of their homes.
  • In May 2021, Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, stated European CE Mark approval of its second-generation Axonics r-SNM implantable neurostimulator (INS) and wireless patient remote control with SmartMRI technology.

Why Purchase the Report?

  • To visualize the global bowel management systems market segmentation-based product type, application, patient type, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analysing trends and co-development
  • Excel data sheet with numerous data points of bowel management systems market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bowel management systems market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Patient Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the technology advancements
      • 4.1.1.2. Rise in the product launches by key players
    • 4.1.2. Restraints
      • 4.1.2.1. Long-term patient rehabilitation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Colostomy Bags*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Irrigation Systems
  • 7.4. Nerve Modulation Devices
  • 7.5. Others

8. By Patient Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.1.2. Market Attractiveness Index, By Patient Type
  • 8.2. Adults*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Pediatric

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Spinal Cord Injury*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Neurological Disorders
  • 9.4. Multiple Sclerosis
  • 9.5. Stroke

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Ambulatory Surgical Centers (ASCs)
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Becton, Dickinson and Company
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Coloplast Pty Ltd.
  • 13.3. ConvaTec Group plc.
  • 13.4. B Braun SE.
  • 13.5. Consure Medical Pvt. Ltd.
  • 13.6. GBUK Group Ltd.
  • 13.7. Wellandmedical
  • 13.8. Wellspect
  • 13.9. ProSys International Ltd
  • 13.10. Qufora

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us